Rate of sentinel lymph node identification using isosulfan blue dye in breast cancer patients at Charoenkrung Pracharak Hospital, Thailand

1. Supraporn S. First annual meeting Thai Breast Disease Society. Bangkok: Thai Breast Breast Society; 2007.Search in Google Scholar

2. Attasara P BR. Hospital-based cancer registry. Bangkok: National Cancer Institute; 2007.Search in Google Scholar

3. Nakamura S. Axillary lymph node dissection in sentinel node positive breast cancer: is it necessary? Curr Opin Obstet Gynecol. 2013 Feb 19. [Epub ahead of print].10.1097/GCO.0b013e32834f3608Search in Google Scholar

4. Moncayo VM, Aarsvold JN, Grant SF, Bartley SC, Alazraki NP. Status of sentinel lymph node for breast cancer. Semin Nucl Med. 2013; 43:281-93.10.1053/j.semnuclmed.2013.02.004Open DOISearch in Google Scholar

5. Wang Z, Wu LC, Chen JQ. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat. 2011; 129:675-89.10.1007/s10549-011-1665-1Search in Google Scholar

6. Park HS, Chae BJ, Song BJ, Jung SS, Han W, Nam SJ, et al. Effect of axillary lymph node dissection after sentinel lymph node biopsy on overall survival in patients with T1 or T2 node-positive breast cancer: report from the Korean Breast Cancer Society. Ann Surg Oncol. 2013 Dec 7.10.1245/s10434-013-3350-6Search in Google Scholar

7. Feig BW BD, Fuhrman GM. Anderson surgical oncology handbook. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p.23-59.Search in Google Scholar

8. Meretoja TJ, Audisio RA, Heikkila PS, Bori R, Sejben I, Regitnig P, et al. International multicenter tool to predict the risk of four or more tumor-positive axillary lymph nodes in breast cancer patients with sentinel node macrometastases. Breast Cancer Res Treat. 2013; 138:817-27.10.1007/s10549-013-2468-3Search in Google Scholar

9. Noguchi M, Morioka E, Ohno Y, Nakano Y, Kosaka T. The changing role of axillary lymph node dissection for breast cancer. Breast Cancer. 2012; 20:41-6.10.1007/s12282-012-0416-4Open DOISearch in Google Scholar

10. Crane-Okada R, Wascher RA, Elashoff D, Giuliano AE. Long-term morbidity of sentinel node biopsy versus complete axillary dissection for unilateral breast cancer. Ann Surg Oncol. 2008; 15:1996-2005.10.1245/s10434-008-9909-yOpen DOISearch in Google Scholar

11. Bafford A, Gadd M, Gu X, Lipsitz S, Golshan M. Diminishing morbidity with the increased use of sentinel node biopsy in breast carcinoma. Am J Surg. 2010; 200:374-7.10.1016/j.amjsurg.2009.10.012Search in Google Scholar

12. Sanuki N, Takeda A, Amemiya A, Ofuchi T, Ono M, Ogata H, et al. Outcomes of clinically node-negative breast cancer without axillary dissection: can preserved axilla be safely treated with radiation after a positive sentinel node biopsy? Clin Breast Cancer. 2012; 13: 69-76.10.1016/j.clbc.2012.09.005Open DOISearch in Google Scholar

13. Boyages J, Winch C. Axillary versus sentinel-lymphnode dissection for micrometastatic breast cancer. Lancet Oncol. 2013; 14:e250-1.10.1016/S1470-2045(13)70218-3Open DOISearch in Google Scholar

14. Wells BJ, Quan ML, Coyte PC. The ever-diminishing role of axillary lymph node dissection in breast cancer. Breast J. 2013; 19:691-2.10.1111/tbj.12196Open DOISearch in Google Scholar

15. Orang E, Marzony ET, Afsharfard A. Predictive role of tumor size in breast cancer with axillary lymph node involvement - can size of primary tumor be used to omit an unnecessary axillary lymph node dissection? Asian Pac J Cancer Prev. 2013; 14:717-22.Search in Google Scholar

16. Ogawa Y, Ikeda K, Ogisawa K, Tokunaga S, Fukushima H, Inoue T, et al. Outcome of sentinel lymph node biopsy in breast cancer using dye alone: a single center review with a median follow-up of 5 years. Surg Today. 2013 Sep 26.10.1007/s00595-013-0728-9Search in Google Scholar

17. Zengel B, Yararbas U, Sirinocak A, Ozkok G, Denecli AG, Postaci H, et al. Sentinel lymph node biopsy in breast cancer: review on various methodological approaches. Tumori. 2013; 99:149-53.10.1177/030089161309900205Search in Google Scholar

18. Kantaraksa N, Kongdan Y, Suvikapakornkul R, Wasutit Y, Chirappapha P, Lertsithichai P. The relative false negative rate of isosulfan blue in detecting sentinel lymph nodes in early breast cancer. J Med Assoc Thai. 2012; 95:181-5.Search in Google Scholar

19. Gill G. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol. 2009; 16:266-75.10.1245/s10434-008-0229-zOpen DOISearch in Google Scholar

20. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006; 106:4-16.10.1002/cncr.21568Open DOISearch in Google Scholar

21. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007; 8:881-8.10.1016/S1470-2045(07)70278-4Open DOISearch in Google Scholar

22. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006; 98:599-609.10.1093/jnci/djj15816670385Open DOISearch in Google Scholar

23. Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010; 251:595-600.10.1097/SLA.0b013e3181c0e92a20195151Search in Google Scholar

24. Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, et al. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008; 247:207-13.10.1097/SLA.0b013e31812e6a7318216523Search in Google Scholar

25. Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast April 19 to 22, 2001, Philadelphia, Pennsylvania. Hum Pathol. 2002; 33:579-89.10.1053/hupa.2002.12411712152156Search in Google Scholar

26. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003; 349:546-53.10.1056/NEJMoa012782Search in Google Scholar

27. Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005; 23:7703-20.10.1200/JCO.2005.08.001Open DOISearch in Google Scholar

28. O’Hea BJ, Hill AD, El-Shirbiny AM, Yeh SD, Rosen PP, Coit DG, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan- Kettering Cancer Center. J Am Coll Surg. 1998; 186: 423-7.10.1016/S1072-7515(98)00060-XSearch in Google Scholar

29. Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg. 1998; 227:645-51; discussion 51-3.10.1097/00000658-199805000-0000511913399605656Search in Google Scholar

30. Canavese G, Gipponi M, Catturich A, Vecchio C, Tomei D, Nicolo G, et al. Technical issues and pathologic implications of sentinel lymph node biopsy in early-stage breast cancer patients. J Surg Oncol. 2001; 77:81-7; discussion 8.10.1002/jso.107411398158Open DOISearch in Google Scholar

31. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994; 220:391-8; discussion 8-401.10.1097/00000658-199409000-0001512344008092905Search in Google Scholar

32. Simmons RM, Smith SM, Osborne MP. Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. Breast J. 2001; 7: 181-3.10.1046/j.1524-4741.2001.007003181.x11469932Open DOISearch in Google Scholar

33. Simmons R, Thevarajah S, Brennan MB, Christos P, Osborne M. Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. Ann Surg Oncol. 2003; 10:242-7.10.1245/ASO.2003.04.02112679308Open DOISearch in Google Scholar

34. Bauer TW, Spitz FR, Callans LS, Alavi A, Mick R, Weinstein SP, et al. Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer. Ann Surg Oncol. 2002; 9:169-76.10.1007/BF0255737011888875Open DOISearch in Google Scholar

35. Zavagno G, Meggiolaro F, Rossi CR, Casara D, Pescarini L, Marchet A, et al. Subareolar injection for sentinel lymph node location in breast cancer. Eur J Surg Oncol. 2002; 28:701-4.10.1053/ejso.2002.134012431465Open DOISearch in Google Scholar

36. Kuerer HM, Wayne JD, Ross MI. Anaphylaxis during breast cancer lymphatic mapping. Surgery. 2001; 129: 119-20.10.1067/msy.2001.111212Open DOISearch in Google Scholar

37. Sleth JC. [Anaphylaxis due to patent blue. Time to change dye?] Ann Fr Anesth Reanim. 2008; 27:515. (in French)10.1016/j.annfar.2008.05.004Open DOISearch in Google Scholar

38. Nason KS, Anderson BO, Byrd DR, Dunnwald LK, Eary JF, Mankoff DA, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer. 2000; 89:2187-94.10.1002/1097-0142(20001201)89:11<2187::AID-CNCR6>3.0.CO;2-#Open DOISearch in Google Scholar

39. Tafra L, Verbanac KM, Lannin DR. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg. 2001; 182:312-5.10.1016/S0002-9610(01)00718-8Open DOISearch in Google Scholar

40. Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006; 93:539-46.10.1002/bjs.5209Open DOISearch in Google Scholar

41. Reitsamer R, Menzel C, Glueck S, Rettenbacher L, Weismann C, Hutarew G. Sentinel lymph node biopsy is precise after primary systemic therapy in stage IIIII breast cancer patients. Ann Surg Oncol. 2010;17 Suppl 3:286-90.10.1245/s10434-010-1246-2Open DOISearch in Google Scholar

42. Shimazu K, Noguchi S. Sentinel lymph node biopsy before versus after neoadjuvant chemotherapy for breast cancer. Surg Today. 2011; 41:311-6.10.1007/s00595-010-4404-zOpen DOISearch in Google Scholar

43. Goyal A, Newcombe RG, Chhabra A, Mansel RE. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer - results of the ALMANAC validation phase. Breast Cancer Res Treat. 2006; 99:203-8. 10.1007/s10549-006-9192-1Open DOISearch in Google Scholar